Compare RLAY & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLAY | PIPR |
|---|---|---|
| Founded | 2015 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 5.5B |
| IPO Year | 2020 | 2003 |
| Metric | RLAY | PIPR |
|---|---|---|
| Price | $19.35 | $72.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $19.50 | ★ $91.38 |
| AVG Volume (30 Days) | ★ 2.8M | 499.4K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | 31.78 | ★ 54.49 |
| EPS | N/A | ★ 1.87 |
| Revenue | $15,355,000.00 | ★ $1,904,217,000.00 |
| Revenue This Year | N/A | $12.30 |
| Revenue Next Year | $324.03 | $13.55 |
| P/E Ratio | ★ N/A | $39.50 |
| Revenue Growth | ★ 53.44 | 24.33 |
| 52 Week Low | $4.32 | $69.16 |
| 52 Week High | $21.27 | $380.26 |
| Indicator | RLAY | PIPR |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 47.65 |
| Support Level | $18.03 | $73.36 |
| Resistance Level | $20.82 | $78.49 |
| Average True Range (ATR) | 0.69 | 1.98 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 20.12 | 50.76 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.